Cannabinoids may provide a treatment option for chronic inflammation, according to a new study published in the FASEB Journal, and published online by the U.S. National Institute of Health.
“Cannabinoids apparently act on inflammation through mechanisms different from those of agents such as nonsteroidal anti-inflammatory drugs (NSAIDs)”, states the study’s abstract. “As a class, the cannabinoids are generally free from the adverse effects associated with NSAIDs. Their clinical development thus provides a new approach to treatment of diseases characterized by acute and chronic inflammation and fibrosis.”
For the study, a “concise survey of the anti-inflammatory actions of the phytocannabinoids Δ9-tetrahydrocannabinol (THC), cannabidiol, cannabichromene, and cannabinol” is presented.
According to researchers; “The review concludes with a presentation of a possible mechanism for the anti-inflammatory and antifibrotic actions of these substances. Thus, several cannabinoids may be considered candidates for development as anti-inflammatory and antifibrotic agents.”
Of special interest, the study states, “is their possible use for treatment of chronic inflammation, a major unmet medical need.”
The full study, conducted by researchers at the University of Massachusetts Medical School, can be found by clicking here.